Sleep & Circadian Peptides — Delta Sleep-Inducing Peptide (DSIP) Research Overview

DSIP (delta sleep-inducing peptide; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; 9 amino acids; MW 848.87 Da; CAS 62568-57-4; C₃₅H₄₈N₁₀O₁₅) was isolated in 1974 from thalamic venous blood of rabbits in deep delta-wave (slow-wave) sleep. Initial research showed that DSIP dialysate transferred from sleeping rabbits to awake animals induced EEG delta-wave activity — the defining slow-wave sleep pattern. DSIP is found endogenously in human cerebrospinal fluid, blood, and brain at picomolar concentrations, with diurnal variation. Despite the name, the 'sleep-inducing' designation does not fully capture DSIP's biology: its sleep effects in acute rodent/human studies are modest and inconsistent, while its effects on GH pulsatility, cortisol/corticotropin rhythms, and stress-protein expression are more consistently reported. DSIP appears to function primarily as a multi-system neuromodulator and circadian oscillator rather than a direct soporific compound.

Key research domains for DSIP: (1) **GH pulsatility regulation** — DSIP co-localizes with GH-releasing neurons and potentiates pulsatile GH secretion in a circadian manner; published pre-clinical and early human data show DSIP enhances nocturnal GH peaks without altering baseline levels, consistent with a circadian-synchronizing role rather than a simple secretagogue effect; (2) **Stress adaptation and stress-protein modulation** — DSIP reduces stress-induced corticosterone surges in rodent models and modulates HSP70 (heat-shock protein 70) expression; published work from Russian and Swiss groups suggests DSIP has adaptogen-like properties in chronic stress models; (3) **Sleep architecture effects** — human studies (primarily from Swiss and German sleep labs, 1970s–1990s) show DSIP administration shifts sleep architecture toward deeper slow-wave sleep stages in some subjects; effects are dose/individual-dependent and not universal; (4) **Neuroprotection and antioxidant effects** — more recent published data (primarily Russian groups) report DSIP antioxidant activity, free-radical scavenging, and neuroprotective effects in oxidative-stress models; (5) **Circadian normalization** — published animal data shows DSIP can re-entrain disrupted circadian rhythms and reduce jet-lag model severity in rodents.

Sleep and circadian research peptides of interest beyond DSIP include: **VIP** (vasoactive intestinal peptide, 28 aa) — released during REM sleep and a key circadian pacemaker in the SCN (suprachiasmatic nucleus); **NPY** (neuropeptide Y) — modulates food intake, circadian timing, and anxiety-sleep interactions; and **GHRH fragments** — GHRH potently promotes slow-wave sleep via GHRH receptor mechanisms in the hypothalamus, connecting the sleep and GH axes (relevant alongside DSIP's own GH pulsatility effects). DSIP remains the most research-accessible sleep neuropeptide: synthetically available at meaningful quantities, well-characterized in pre-clinical models, and commercially available. DMV Research supplies DSIP (delta sleep-inducing peptide) as a lyophilized research compound with per-batch Certificate of Analysis confirming identity and purity for in-vitro and pre-clinical laboratory research applications.